Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [1] Combined Administration of Quinidine and Propafenone for Atrial Fibrillation: The CAQ-PAF Study
    O'Hara, Gilles E.
    Philippon, Francois
    Gilbert, Marcel
    Champagne, Jean
    Michaud, Veronique
    Charbonneau, Lyne
    Pruneau, Guylaine
    Hamelin, Bettina A.
    Geelan, Peter
    Turgeon, Jacques
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (02) : 171 - 179
  • [2] Efficacy of Dronedarone Versus Propafenone in the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After Electrical Cardioversion
    Chun, Kwang Jin
    Byeon, Kyeongmin
    Im, Sung Il
    Park, Kyoung-Min
    Park, Seung-Jung
    Kim, June Soo
    On, Young Keun
    CLINICAL THERAPEUTICS, 2014, 36 (09) : 1169 - 1175
  • [3] An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation
    Chin, Chye-Gen
    Hsieh, Yu-Cheng
    Lin, Wei-Shiang
    Lin, Yenn-Jiang
    Chiou, Chuen-Wang
    Lin, Tsung-Hsien
    Huang, Chien-Lung
    Hung, Yuan
    Lin, Yung-Kuo
    Chang, Shih-Lin
    Yeh, Tong-Chen
    Lee, Hsiang-Chun
    Lai, Wen-Ter
    Hsieh, Ming-Hsiung
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (05) : 472 - 478
  • [4] Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines
    Savelieva, Irene
    Graydon, Richard
    Camm, A. John
    EUROPACE, 2014, 16 (02): : 162 - 173
  • [5] New Pharmacological Strategies for the Treatment of Atrial Fibrillation
    Burashnikov, Alexander
    Antzelevitch, Charles
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2009, 14 (03) : 290 - 300
  • [6] Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment
    Alboni, Paolo
    Botto, Giovanni L.
    Boriani, Giuseppe
    Russo, Giovanni
    Pacchioni, Federico
    Iori, Matteo
    Pasanisi, Giovanni
    Mancini, Marina
    Mariconti, Barbara
    Capucci, Alessandro
    HEART, 2010, 96 (07) : 546 - 549
  • [7] Quinidine for Pharmacological Cardioversion of Atrial Fibrillation: A Retrospective Analysis in 501 Consecutive Patients
    Schwaab, Bernhard
    Katalinic, Alexander
    Boege, Uta Maria
    Loh, Juergen
    Blank, Peter
    Koelzow, Tatjana
    Poppe, Dirk
    Bonnemeier, Hendrik
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2009, 14 (02) : 128 - 136
  • [8] Advances in the treatment of atrial fibrillation
    Capucci, Alessandro
    Compagnucci, Paolo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2021, 22 (09) : 689 - 696
  • [9] Pharmacological approaches in the treatment of atrial fibrillation
    Tamargo, J
    Caballero, R
    Deplón, E
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (01) : 13 - 28
  • [10] Propafenone Versus Vernakalant for Conversion of Recent-Onset Atrial Fibrillation
    Conde, Diego
    Pablo Costabel, Juan
    Aragon, Martin
    Lambardi, Florencia
    Klein, Andres
    Corrales Barbosa, Andrea
    Trivi, Marcelo
    Giniger, Alberto
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (06) : 377 - 380